Safety profile of bortezomib in patients treated at the recommended doses on each schedule or at lower doses on either schedule
| AEs, n (%) . | Recommended dose groups . | Lower doses (N = 18) . | |
|---|---|---|---|
| 1.6 mg/m2 QW (N = 18) . | 1.3 mg/m2 BIW (N = 34) . | ||
| Any AE | 18 (100) | 34 (100) | 18 (100) |
| Any treatment-related AE | 17 (94) | 33 (97) | 17 (94) |
| Any grade ≥ 3 AE | 9 (50) | 27 (79) | 7 (39) |
| Any grade 4 AE | 2 (11) | 6 (18) | 0 |
| Any serious AE | 8 (44) | 14 (41) | 3 (17) |
| Patients discontinuing because of AEs | 5 (28) | 13 (38) | 5 (28) |
| Patients requiring dose reductions because of AEs | 4 (22) | 18 (53) | 1 (6) |
| AEs, n (%) . | Recommended dose groups . | Lower doses (N = 18) . | |
|---|---|---|---|
| 1.6 mg/m2 QW (N = 18) . | 1.3 mg/m2 BIW (N = 34) . | ||
| Any AE | 18 (100) | 34 (100) | 18 (100) |
| Any treatment-related AE | 17 (94) | 33 (97) | 17 (94) |
| Any grade ≥ 3 AE | 9 (50) | 27 (79) | 7 (39) |
| Any grade 4 AE | 2 (11) | 6 (18) | 0 |
| Any serious AE | 8 (44) | 14 (41) | 3 (17) |
| Patients discontinuing because of AEs | 5 (28) | 13 (38) | 5 (28) |
| Patients requiring dose reductions because of AEs | 4 (22) | 18 (53) | 1 (6) |
QW indicates once weekly; and BIW, twice weekly.